Patients undergoing CT colonography, also known as virtual colonoscopy, now take four tablets of the cleansing agent bisacodyl. Mayo instituted the new protocol this summer.
“Our hope is that this will make people less anxious and more likely to get screened and will ultimately result in fewer deaths from colorectal cancer,” said C. Daniel Johnson, MD, chair of the department of radiology at Mayo Clinic in Arizona, in the release.
The protocol was based on a study co-authored by Dr. Johnson that was published in Abdominal Imaging last year. The study found the four-tablet procedure was as effective as the standard liquid laxative for virtual colonoscopies.
The new protocol is not intended for standard colonoscopies.
Related Articles on Gastroenterology:
Study: Narrow Band Imaging Accuracy With Colonoscopy Allows Distal Non-Cancerous Polyps to Remain
Gastroenterologist on the Move: Dr. Kabir Julka Joins IL’s Dreyer Medical Clinic
Crospon Received FDA Clearance for EndoFLIP Gastroenterology Application
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
